abstract |
The present invention relates to CCR3 inhibitors of formula 1, n n n n n n n n n n whereinn R 1 is H, C 1-6 -alkyl, C 0-4 -alkyl-C 3-6 -cycloalkyl, C 1-6 -haloalkyl; R 2 is H, C 1-6 -alkyl; X is an anion selected from the group consisting of chloride or ½ dibenzoyltartrate j is 1 or 2.n nfor use as a medicament for the treatment of diseases selected from dry age-related macular degeneration (dAMD), wet age-related macular degeneration (wAMD), retinopathy of prematurity (ROP), central retinal vein occlusion (CRVO), nasal polyposis, eosinophilic esophagitis, eosinophillic gastroenteritis (e.g. eosinophilic gastritis and eosinophilic ententeritis), hypereosinophilic syndrome and Churg Strauss syndrome. |